Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Study Reveals Basis for Development of a Universal Flu Vaccine

By BiotechDaily International staff writers
Posted on 26 Mar 2013
Researchers attempting to develop a "universal" flu vaccine have suggested that a multifocal approach based on primed immune cells and virus specific non-neutralizing antibodies may result in long-term protection from multiple strains of the influenza virus.

Investigators at the University of Pennsylvania (Philadelphia, USA) based their work on studies that showed that T lymphocytes were capable of mediating protection against multiple viral strains through recognition of internal, more conserved, influenza virus proteins.

They reported in the March 14, 2013, online edition of the journal PLOS Pathogens that influenza virus-specific CD8+ T-cells or virus-specific non-neutralizing antibodies were each relatively ineffective at conferring protective immunity alone. However, when administered together virus-specific CD8 T-cells and non-neutralizing antibodies cooperatively elicited robust protective immunity. This synergistic improvement in protective immunity was dependent, at least in part, on alveolar macrophages and/or other lung phagocytes.

“The two-pronged approach is synergistic, so by enlisting two suboptimal vaccine approaches, we achieved a better effect than each alone in an experimental model,” said senior author Dr. E. John Wherry, associate professor of microbiology at the University of Pennsylvania,. “Now, we are rethinking past approaches and looking for ways to combine T-cell vaccines and antibody vaccines to make a more effective combined vaccine. Overall, our studies suggest that an influenza vaccine capable of eliciting both CD8+ T-cells and antibodies specific for highly conserved influenza proteins may be able to provide protection in humans, and act as the basis for a potential "universal" vaccine.”

Related Links:
University of Pennsylvania



Channels

Genomics/Proteomics

view channel
Image: The TheraCyte cell encapsulation device (Photo courtesy of TheraCyte, Inc.).

Encapsulated Human-Insulin-Producing Progenitor Cells Cure Diabetes in Mouse Model

A breakthrough system that allows subcutaneous implantation of encapsulated immature pancreatic cells (beta progenitor cells) was shown to produce enough insulin to correct the symptoms of diabetes in a mouse model.... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.